Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05251701Completed

Personal KinetiGraph® Clinical Validation Study

Role: lead

NCT03741920Not ApplicableActive Not Recruiting

Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status

Role: lead

NCT03984305Not ApplicableTerminated

Utilization of Target Ranges to Treat Parkinson's Disease With the PKG

Role: lead

NCT04381065Not ApplicableWithdrawn

Utilization of Target Ranges to Treat Persons With Parkinson's Disease by Objective Measurement Using the PKG

Role: lead

All 4 trials loaded